Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2025 > Richard Pazdur

Richard Pazdur

Richard Pazdur

Read also

AstraZeneca reports positive results from phase 3 blood pressure trial

AstraZeneca reports positive results from phase 3 blood pressure trial

AstraZeneca has announced positive results from its Bax24 trial of baxdrostat, an investigational treatment for hypertension, demonstrating clinically meaningful reductions in systolic blood pressure ...

Optimizing Preclinical Data for Seamless Translation in Clinical Scenarios

Optimizing Preclinical Data for Seamless Translation in Clinical Scenarios

According to Greg Thurber, PhD, target-mediated uptake is the biggest driver of efficacy for antibody-drug conjugates as a cancer treatment.

FDA Approves Caplyta for Major Depressive Disorder in Adults

FDA Approves Caplyta for Major Depressive Disorder in Adults

THURSDAY, Nov. 13, 2025 -- The U.S. Food and Drug Administration has approved Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major depressive disorde...

Metagenomi sheds 25% of workforce

Metagenomi sheds 25% of workforce

Metagenomi sheds 25% of workforce, including CEO, to focus on preclinical hemophilia program